Hepatic injury is a frequent complication of hematopoietic SCT and carries a high risk for early morbidity and mortality. Early hepatic complications include drug toxicity, veno-occlusive disease, acute GVHD, infection and cholestatic disorders. 1 Risk evaluation for hepatic complications should begin in the pre transplant period with the identification of risk factors that may be associated with development of hepatic dysfunction post-transplant, such as viral hepatitis status or elevated liver enzymes before the start of conditioning. Transient elastography (FibroScan) is a non-invasive and reproducible method for the assessment of hepatic fibrosis in patients with chronic liver disease by measuring liver stiffness (LS). 2, 3 LS is also a surrogate marker for significant necroinflammation or extrahepatic cholestasis in the absence of fibrosis. TE has been assessed in chronic hepatitis B, hepatitis C, co-infection with HIV, non-alcoholic fatty liver disease, primary biliary cirrhosis and primary sclerosing cholangitis, and it also has been validated for evaluation of fibrosis in the post-liver transplant setting. 4, 5 The primary aim of the current single-center analysis was to evaluate whether the use of pre transplant non-invasive transient elastography might be predictive for post-transplant liver toxicity. We therefore incorporated the investigation into our routine pre transplant work-up program. All patients gave written informed consent. Patient characteristics are summarized in Table 1 . Conditioning regimens for Auto-SCT were CY (total dose 120 mg/kg) in combination with fractionated TBI (12 gray) or i.v. BU (total dose 12.8 mg/kg) for acute leukemia (n ¼ 2), BEAM for lymphoma (n ¼ 16), high-dose melphalan (total dose 200 mg/kg) for plasma cell disorders (n ¼ 14) and i.v. BU (total dose 12.8 mg/ kg) with high-dose melphalan (total dose 140 mg/kg) for solid tumors (n ¼ 4). For allo-SCT-conditioning the regimen consisted of standard-dose BUCY or BUMEL (n ¼ 16) or CY (total dose 120 mg/ kg) ±VP-16 (total dose 20-40 mg/kg) and fractionated TBI (12 Gy) (n ¼ 2) for myeloablative transplants and mainly BU (total dose 6.4-12.8 mg/kg)-FLU (total dose 90 mg/kg)-based regimen for dose-reduced transplants (n ¼ 12). Statistical analyses were completed using using GraphPad Prism 4.0 (GraphPad Software, Inc., San Diego, CA, USA) with a 5% level of significance.
Despite liver problems in the setting of hematopoietic SCT having become less frequent, because of a better understanding of how to prevent and treat most of the serious hepatobiliary complications and a wider use of reduced-intensity conditioning regimens, alterations of liver function still affect more than 50% of the patients following allo-SCT. 1 Although some risk factors have been identified in the past no test including imaging techniques can exactly predict the risk for developing liver toxicity following SCT. To our knowledge this is the first report on a possible role of transient elastography, a novel, rapid and user-and patient-friendly technique, for identifying patients with a high risk for developing liver complications following hematopoietic SCT.
The median LS before transplant determined by transient elastography was 5.4 kPa (range, 2.3-62.7). LS significantly correlated with pre transplant AST and ALT values in the entire cohort and with ALT, GGT and AP levels in patients with signs of more severe liver toxicity having bilirubin levels42.0 mg/dL for more than 10 days within the first 20 days after transplant. Overall, 24/67 (36%) patients had an increase of total serum bilirubin 42 mg/dL within the first 20 days post hematopoietic SCT. The median maximal total serum bilirubin for the entire cohort within 20 days from SCT was 1.18 (range, 0.44-11.72) mg/dL, the median number of days with a total serum bilirubinX2.0 mg/dL was 10.5 (range, 1-20) days and the maximal weight gain was 5.2% (range, 0.1-17.2%). For allogeneic transplants liver toxicity (that is, increase of total serum bilirubin 42.0 mg/dL) was significantly more frequent after myeloablative vs dose-reduced conditioning (16/19 vs 6/12 patients, that is, 84% vs 50%, respectively; P ¼ 0.04, w 2 -test) and only 2/36 (6%) patients had signs of liver toxicity following ASCT (2/36 patients., 6%). Maximal total serum bilirubin was significantly higher in patients with pre transplant LS values 48.0 kPa when compared with patients with a pre transplant LS o8.0 kPa (2.31 ± 0.33 mg/dL vs 4.34 ± 1.20 mg/dL; P value 0.0272, unpaired t-test, Figure 1) .
Summarizing, by using a cutoff value of 8.0 kPa based on several studies and meta-analyses in patients with chronic liver disease showing an optimal diagnostic accuracy for significant fibrosis in patients with LS values 47.6 kPa we could discriminate patients with a mean post-transplant total serum bilirubin of 4.34 mg/dL. non-relapse mortality. 6 If validated in a larger cohort of patients transient elastography might help to better identify candidates for non-myeloablative or reduced-intensity instead of myeloablativeconditioning regimen and/or the prophylactic use of defibrotide, which has been shown to be effective in prophylaxis and treatment of liver disease following pediatric SCT. 
